Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men

American Journal of Physiology - Endocrinology and Metabolism

Volumn 308, Issue 8, 2015, Pages E641-E649

  Asmar, Ali ^a   Simonsen, Lene ^a   Asmar, Meena ^a   Madsbad, Sten ^b   Holst, Jens J ^c   Frandsen, Erik ^d   Moro, Cedric ^e   Jonassen, Thomas ^c   Bülow, Jens ^a,c  

^a BISPEBJERG HOSPITAL   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^e CNRS   (France)

Author keywords

Blood pressure; Cardiac output; Glucagon like peptide 1; Heart rate; Renal plasma flow

Indexed keywords

ATRIAL NATRIURETIC FACTOR; GLUCAGON LIKE PEPTIDE 1; LITHIUM ION; SODIUM ION; GLUCAGON-LIKE PEPTIDE-1 (9-36)-AMIDE; PEPTIDE; RENIN;

ADULT; ARTERIAL PRESSURE; ARTICLE; CENTRAL HEMODYNAMIC; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ELECTROLYTE URINE LEVEL; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEMODYNAMICS; HORMONE RELEASE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; MALE; MIDDLE AGED; NORMAL HUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE PRESSURE; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; URINE PH; URINE VOLUME; VEIN CATHETERIZATION; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BLOOD; BLOOD PRESSURE; CATHETERIZATION; CIRCULATION; COMPARATIVE STUDY; ELECTROLYTE BALANCE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; KIDNEY CIRCULATION; KIDNEY VEIN; METABOLISM; PHYSIOLOGY; RADIAL ARTERY; SECRETION (PROCESS); URINARY EXCRETION; URINE; VASCULARIZATION;

BLOOD CIRCULATION; BLOOD PRESSURE; CARDIAC OUTPUT; CATHETERIZATION; GLOMERULAR FILTRATION RATE; GLUCAGON-LIKE PEPTIDE 1; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PEPTIDES; RADIAL ARTERY; RENAL CIRCULATION; RENAL ELIMINATION; RENAL VEINS; RENIN; WATER-ELECTROLYTE BALANCE;

EID: 84929648698     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00429.2014     Document Type: Article

References (35)

1. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptordependent and -independent pathways. Circulation 117: 2340-2350, 2008.
2. Bharucha AE, Charkoudian N, Andrews CN, Camilleri M, Sletten D, Zinsmeister AR, Low PA. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol 295: R874-R880, 2008.
3. Bie P. Blood volume, blood pressure and total body sodium: internal signalling and output control. Acta Physiol (Oxf) 195: 187-196, 2009.
4. Bie P, Wamberg S, Kjolby M. Volume natriuresis vs. pressure natriuresis. Acta Physiol Scand 181: 495-503, 2004.
5. Calara F, Taylor K, Han J, Zabala E, Carr EM, Wintle M, Fineman M. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther 27: 210-215, 2005.
6. Davidson MH. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol 108: 33b-41b, 2011.
7. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 53: 2397-2403, 2004.
8. Filler G, Yasin A, Medeiros M. Methods of assessing renal function. Pediatr Nephrol 29: 183-192, 2014.
9. Gallwitz B, Vaag A, Falahati A, Madsbad S. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. Int J Clin Pract 64: 267-276, 2010.
10. Greenleaf JE, Petersen TW, Gabrielsen A, Pump B, Bie P, Christensen NJ, Warberg J, Videbaek R, Simonson SR, Norsk P. Low LBNP tolerance in men is associated with attenuated activation of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 279: R822-R829, 2000.
11. Gustavson SM, Chen D, Somayaji V, Hudson K, Baltrukonis DJ, Singh J, Boyden TL, Calle RA. Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus. Diabetes Obes Metab 13: 1056-1058, 2011.
12. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89: 3055-3061, 2004.
13. Henriksen UL, Henriksen JH. The clearance concept with special reference to determination of glomerular filtration rate in patients with fluid retention. Clin Physiol Funct Imaging 35: 7-16, 2015.
14. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439, 2007.
15. Imholz BP, Wieling W, van Montfrans GA, Wesseling KH. Fifteen years experience with finger arterial pressure monitoring: assessment of the technology. Cardiovasc Res 38: 605-616, 1998.
16. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 19: 567-575, 2013.
17. Korner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 48: 736-743, 2007.
18. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, Drucker DJ. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 55: 167-194, 2003.
19. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53: 654-662, 2004.
20. Mendis B, Simpson E, MacDonald I, Mansell P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol 74: 437-444, 2012.
21. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, Sjoholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287: E1209-E1215, 2004.
22. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 23: 334-339, 2010.
23. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539, 1994.
24. Persson P, Hansell P, Palm F. Tubular reabsorption and diabetes-induced glomerular hyperfiltration. Acta Physiol (Oxf) 200: 3-10, 2010.
25. Pyke C, Heller RS, Kirk RK, Orskov C, Reedtz-Runge S, Kaastrup P, Hvelplund A, Bardram L, Calatayud D, Knudsen LB. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155: 1280- 1290, 2014.
26. Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept 141: 120-128, 2007.
27. Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 49: 706-712, 2006.
28. Sivertsen J, Rosenmeier J, Holst JJ, Vilsboll T. The effect of glucagonlike peptide 1 on cardiovascular risk. Nat Rev Cardiol 9: 209-222, 2012.
29. Skov J, Dejgaard A, Frokiaer J, Holst JJ, Jonassen T, Rittig S, Christiansen JS. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 98: E664-E671, 2013.
30. Skov J, Holst JJ, Gotze JP, Frokiaer J, Christiansen JS. Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. Endocr Connect 3: 11-16, 2014.
31. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22: 1137-1143, 1999.
32. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, Holst JJ. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88: 2706-2713, 2003.
33. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 358: 219-224, 1995.
34. Wettergren A, Wojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol Gastrointest Liver Physiol 275: G984-G992, 1998.
35. Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40: 597-601, 1997.